Tianjin Tianyao Pharmaceuticals (600488) Fundamentals 2026 — P/E 207.3x, Revenue Analysis | SniperIQ
Tianjin Tianyao Pharmaceuticals (600488) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥5.5B, trading at ¥5.08 on the SHH. This SniperIQ fundamentals page covers Tianjin Tianyao Pharmaceuticals's valuation (P/E 207.3x, P/B 1.8x), profitability (net margin 1.0%), revenue (¥2.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tianjin Tianyao Pharmaceuticals's market cap?
Tianjin Tianyao Pharmaceuticals (600488) has a market capitalization of approximately ¥5.5B, trading at ¥5.08 on the SHH. Market cap moves with the live share price.
What is Tianjin Tianyao Pharmaceuticals's P/E ratio?
Tianjin Tianyao Pharmaceuticals's trailing twelve-month P/E ratio is 207.3x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tianjin Tianyao Pharmaceuticals?
Tianjin Tianyao Pharmaceuticals runs a net profit margin of 1.0%, a gross margin of 41.2%, and an operating margin of 4.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tianjin Tianyao Pharmaceuticals generate?
Tianjin Tianyao Pharmaceuticals reported revenue of ¥2.9B for fiscal year 2025, with net income of ¥71M and earnings per share (EPS) of 0.065. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tianjin Tianyao Pharmaceuticals pay a dividend?
Tianjin Tianyao Pharmaceuticals offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tianjin Tianyao Pharmaceuticals financially healthy?
Tianjin Tianyao Pharmaceuticals carries a debt-to-equity ratio of 0.25x and a current ratio of 2.08x, with a market beta of 0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tianjin Tianyao Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tianjin Tianyao Pharmaceuticals (600488) the key facts are: market cap ¥5.5B, P/E 207.3x, revenue ¥2.9B, 52-week range 3.68-8.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tianjin Tianyao Pharmaceuticals's full fundamentals live
Get Tianjin Tianyao Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.